Shionogi's mid-stage stroke drug redasemtide fails, while Bayer's Hyrnuo receives expanded NSCLC label

Shionogi reported that its experimental stroke therapy redasemtide did not achieve the primary endpoint in a mid-stage clinical trial, marking a setback for the company’s neurology pipeline.

The failure means the drug will not move forward to later phases at this time, and Shionogi may need to reassess its development strategy for stroke treatments.

In contrast, Bayer announced that its lung‑cancer therapy Hyrnuo has been granted an expanded indication for non‑small cell lung cancer, broadening the patient population that can benefit from the drug.

The label extension is expected to boost Bayer’s sales prospects in the oncology market and reflects positive regulatory feedback.

Both developments highlight the divergent outcomes that can occur in the pharmaceutical industry, with one company facing a trial disappointment while another secures a regulatory win.